Clinical TrialJun 2, 2026, 04:02 PM
Syndax Revuforj shows 90% 2-year OS post-transplant
AI Summary
Syndax Pharmaceuticals presented new Revuforj® (revumenib) data at the ASCO 2026 Annual Meeting, highlighting favorable outcomes in a pooled analysis of 24 acute leukemia patients who resumed revumenib post-transplant. The data showed a 2-year overall survival rate of 90%, significantly higher than the historical benchmark of 51%. Additionally, pharmacokinetic data indicated that revumenib can be administered with gastric acid reducing agents without compromising efficacy. Syndax plans further research in the post-transplant setting, including the MenTain study, a randomized, placebo-controlled trial.
Key Highlights
- Revuforj showed 90% 2-year overall survival in 24 acute leukemia patients post-transplant.
- This compares favorably to a 51% historical 2-year overall survival rate.
- 1-year cumulative relapse rate was 0% for CR1 and 17% for CR2+ patients.
- Historical 1-year relapse rates were 12% for CR1 and 40% for CR2+ patients.
- Median follow-up was 21 months; median OS and event-free survival not reached.
- Revuforj can be administered with gastric acid reducing agents without reduced efficacy.
- Thrombocytopenia was the most common adverse event, leading to 46% dose modification.
Price Impact
More from SNDX